比较吉非替尼与厄洛替尼在非小细胞肺癌中的疗效及安全性

目的 比较吉非替尼和厄洛替尼治疗非小细胞肺癌(NSCLC)的疗效和安全性.方法 回顾性分析中山大学附属第五医院44例患者的临床资料,均口服吉非替尼 250 mg,1次/d或厄洛替尼 150 mg,1次/d,直至病情进展,比较两组的疗效,无进展生存时间及不良反应.结果 吉非替尼和厄洛替尼两组患者的有效率分别为29.2%和25%(P=0.757),疾病控制率为83.3%和75%(P=0.162),无进展生存时间为7.6个月和6.2个月(P=0.995),两组差异均无统计学意义.不良反应如腹泻、皮疹等发生也相似.结论 吉非替尼和厄洛替尼治疗晚期NSCLC疗效和安全性相似.

Comparation of clinical effects and safety between Gefitinib and Erlotinib in treatment of patients with NSCLC

Objective To analyze the clinical outcomes and safety between Gefitinib and Erlotinib in treatment of patients with stage IIIB IV NSCLC.Methods A total of 44 patients who had received Gefitinib or Erlotinib therapy between 2006 and 2010 were retrospectively reviewed.The patients were given respectively Gefitinib（250 mg,QD） or Erlotinib（150 mg,QD） till disease progression.The clinical outcomes and adverse reactions were compared between the two groups.Results The overall response rates,disease control rates and progression free survival in the Gefitinib group and erlotinib group were 29.2% versus 25%（P=0.757）,83.3% versus 75%（P=0.162） and 7.6 months versus 6.2 months（P=0.995） respectively.There was no statistically significant difference.The common toxic effects,such as skin rash and diarrhea,were similar in the two groups.Conclusions Gefitinib and Erlotinib appear to have similar antitumor activity and safety in patients with stage IIIB and IV NSCLC.